hb-202
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2022 (NCT05108870)
Timeline
Indications
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068582 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06513884 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2024 | Hookipa Biotech |
| NCT05108870 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2022 | University of Chicago |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hookipa Biotech | For profit | 1 | 1 | 1 | 2024 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1